Next-generation Immunotherapies for Cancer
Our laboratory focuses on the study of the mechanisms of relapse after chimeric antigen receptor T cell (CART) immunotherapy with the goal of rationally design innovative next-generation immunotherapies for relapsing/refractory leukemia and lymphoma.
For more information, please visit the links below.
CCI Faculty Website Perelman School of Medicine Faculty Page
If you would like to make a monetary contribution, please see the link below. Thank you in advance for your support!
Select "Special Reason" and leave a note: “Donation to fund Dr. Marco Ruella’s research.
Talks & Lectures
-
Advances in CAR-T Therapies: Understanding Resistance to CART immunotherapy to Develop Next Generation Therapies
Tuesday, May 3, 2022
Tuesday, April 5, 2022
5:30 pm
At PEGS Boston Conference Meeting
-
CART Cells for Adult ALL, at
Wednesday, May 18, 2022
Wednesday, May 18, 2022
At the New Drugs for Hematology meeting in Bologna, Italy